2024 IPO

ArriVent Biopharma Stock

ArriVent develops pharmaceutical products to cure presently untreatable cancer.

Sign up today and learn more about ArriVent Biopharma Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About ArriVent Biopharma Stock

ArriVent is a biopharmaceutical company developing pharmaceutical products to cure presently untreatable cancer.

Funding History

June 2021$81.0M
February 2022$69.0M
December 2022$155M

Management

SVP, Development Operations & Business Systems

Morgan Lam

CMO and Co-Founder

Stuart Lutzker

Chairman, Co-founder and Chief Executive Officer

Bing Yao

Chief Business OfficerChief Business Officer

DanDan Dong

CEO and Chairman of Board of Directors

Bing Yao

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo